Stock listing
Cytomed Therapeutics Limited
Selected listing: GDTC · NASDAQ · USD · US
Cytomed Therapeutics Limited (NASDAQ:GDTC), Health Technology. Latest release May 6, 2026: CytoMed Therapeutics : Audited Financial Statements for FY2025.
- Ticker
- NASDAQ:GDTC
- Asset type
- Stock
- Sector
- Health Technology
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Currency
- USD
About Cytomed Therapeutics Limited
The company focuses on developing innovative therapeutic solutions. Investors can find more information about its operations and performance on its public company page.
Latest news from Cytomed Therapeutics Limited
CytoMed Therapeutics : Audited Financial Statements for FY2025
May 6, 2026
CytoMed Therapeutics Refutes Misleading Claims and Reaffirms Clinical Progress
January 28, 2026
CytoMed Therapeutics’ new year update and seeks shareholders’ feedback on proposal to improve shareholder value for their patient capital
January 13, 2026
CytoMed Therapeutics Announces Novel First-In-Human Clinical Trial Collaborations with Renowned and Prestigious Hospital Partner to Advance Its Off-The-Shelf Donor-Derived Gamma Delta T Cells Allogeneic Technology to Treat Cancers in Malaysia
December 8, 2025
CytoMed Therapeutics Completes Acquisition of T Cell Technology from UK to Treat Cancers in China and India
November 18, 2025
Events
Replays
CytoMed Therapeutics Limited (GDTC) Q2 2025 Earnings Call
Thu, Oct 02, 2025 · 10:00 AM ET
Watch
Research Cytomed Therapeutics Limited
Cytomed Therapeutics Limited company profile
View the public company page for Cytomed Therapeutics Limited on 6ix.
Cytomed Therapeutics Limited news
Read company news and market updates connected to Cytomed Therapeutics Limited.
Cytomed Therapeutics Limited investor events
Find investor webinars, events, and replay context for Cytomed Therapeutics Limited.